Finch Therapeutics Group Stock Cash And Equivalents
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Finch Therapeutics Group fundamentals help investors to digest information that contributes to Finch Therapeutics' financial success or failures. It also enables traders to predict the movement of Finch Pink Sheet. The fundamental analysis module provides a way to measure Finch Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Finch Therapeutics pink sheet.
Finch |
Finch Therapeutics Group Company Cash And Equivalents Analysis
Finch Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Finch Therapeutics Cash And Equivalents | 104.67 M |
Most of Finch Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Finch Therapeutics Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Finch Therapeutics Group has 104.67 M in Cash And Equivalents. This is 87.25% lower than that of the Biotechnology sector and 76.59% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 96.13% higher than that of the company.
Finch Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Finch Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics of similar companies.Finch Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Finch Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 53.48 % | ||||
| Shares Owned By Institutions | 11.35 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K | ||||
| Gross Profit | (57.03 M) | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (74.75 M) | ||||
| Cash And Equivalents | 104.67 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 30.13 M | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 7.28 X | ||||
| Book Value Per Share | 11.86 X | ||||
| Cash Flow From Operations | (31.5 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (6.59) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 90.0 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 1.94 M | ||||
| Total Asset | 71 M | ||||
| Retained Earnings | (350.39 M) | ||||
| Working Capital | 21.76 M | ||||
| Net Asset | 71 M |
About Finch Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Finch Therapeutics Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges |